Literature DB >> 23912476

Adjunct low-molecular-weight heparin to improve live birth rate after recurrent implantation failure: a systematic review and meta-analysis.

Neelam Potdar1, Tarek A Gelbaya, Justin C Konje, Luciano G Nardo.   

Abstract

BACKGROUND Poor fertility outcomes in women with recurrent implantation failure (≥ RIF) present significant challenges in assisted reproduction, and various adjuncts, including heparin, are used for potential improvement in pregnancy rates. We performed this systematic review and meta-analysis to evaluate the effect of low-molecular-weight heparin (LMWH) on live birth rates (LBRs) and implantation rates (IRs) in women with RIF and undergoing IVF. METHODS Studies comparing LMWH versus control/placebo in women with RIF were searched for on MEDLINE, EMBASE, Cochrane Library, conference proceedings and databases for registered and ongoing trials (1980-2012). Statistical analysis was performed using Review Manager 5.1. The main outcome measure was LBR per woman. RESULTS Two randomized controlled trials (RCTs) and one quasi-randomized trial met the inclusion criteria. One study included women with at least one thrombophilia ( Qublan et al., 2008) and two studies included women with unexplained RIF ( Urman et al., 2009; Berker et al., 2011). Pooled risk ratios in women with ≥ 3 RIF (N = 245) showed a significant improvement in the LBR (risk ratio (RR) = 1.79, 95% confidence interval (CI) = 1.10-2.90, P = 0.02) and a reduction in the miscarriage rate (RR = 0.22, 95% CI = 0.06-0.78, P = 0.02) with LMWH compared with controls. The IR for ≥ 3 RIF (N = 674) showed a non-significant trend toward improvement (RR = 1.73, 95% CI 0.98-3.03, P = 0.06) with LMWH. However, the beneficial effect of LMWH was not significant when only studies with unexplained RIF were pooled. The summary analysis for the numbers needed to be treated with LMWH showed that approximately eight women would require treatment to achieve one extra live birth. CONCLUSIONS In women with ≥3 RIF, the use of adjunct LMWH significantly improves LBR by 79% compared with the control group; however, this is to be considered with caution, since the overall number of participants in the studies was small. Further evidence from adequately powered multi-centered RCTs is required prior to recommending LMWH for routine clinical use. This review highlights the need for future basic science and clinical research in this important field.

Entities:  

Keywords:  IVF; heparin; low-molecular-weight heparin; recurrent implantation failure; thrombophilia

Mesh:

Substances:

Year:  2013        PMID: 23912476     DOI: 10.1093/humupd/dmt032

Source DB:  PubMed          Journal:  Hum Reprod Update        ISSN: 1355-4786            Impact factor:   15.610


  16 in total

Review 1.  In vitro Fertilization Procedures with Embryo Transfer and Their Association with Thrombophilia, Thrombosis and Early Antithrombotic Treatments.

Authors:  Pierpaolo Di Micco; Vincenzo Russo; Daniela Mastroiacovo; Marijan Bosevski; Corrado Lodigiani
Journal:  J Blood Med       Date:  2020-06-11

2.  Optimization of bioprocess conditions improves production of a CHO cell-derived, bioengineered heparin.

Authors:  Jong Youn Baik; Hussain Dahodwala; Eziafa Oduah; Lee Talman; Trent R Gemmill; Leyla Gasimli; Payel Datta; Bo Yang; Guoyun Li; Fuming Zhang; Lingyun Li; Robert J Linhardt; Andrew M Campbell; Stephen F Gorfien; Susan T Sharfstein
Journal:  Biotechnol J       Date:  2015-06-24       Impact factor: 4.677

3.  A clinicopathological study of episomal papillomavirus infection of the human placenta and pregnancy complications.

Authors:  Tania L Slatter; Natalie Gly Hung; William M Clow; Janice A Royds; Celia J Devenish; Noelyn A Hung
Journal:  Mod Pathol       Date:  2015-08-21       Impact factor: 7.842

Review 4.  'To test or not to test', the arguments for and against thrombophilia testing in obstetrics.

Authors:  Laura Ormesher; Louise E Simcox; Clare Tower; Ian A Greer
Journal:  Obstet Med       Date:  2017-03-08

5.  American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy.

Authors:  Shannon M Bates; Anita Rajasekhar; Saskia Middeldorp; Claire McLintock; Marc A Rodger; Andra H James; Sara R Vazquez; Ian A Greer; John J Riva; Meha Bhatt; Nicole Schwab; Danielle Barrett; Andrea LaHaye; Bram Rochwerg
Journal:  Blood Adv       Date:  2018-11-27

Review 6.  Thrombophilia and assisted reproduction technology-any detrimental impact or unnecessary overuse?

Authors:  Baris Ata; Bulent Urman
Journal:  J Assist Reprod Genet       Date:  2016-07-16       Impact factor: 3.412

Review 7.  The physiologic and therapeutic role of heparin in implantation and placentation.

Authors:  Michela Quaranta; Offer Erez; Salvatore Andrea Mastrolia; Arie Koifman; Elad Leron; Tamar Eshkoli; Moshe Mazor; Gershon Holcberg
Journal:  PeerJ       Date:  2015-01-06       Impact factor: 2.984

8.  Low-molecular-weight-heparin can benefit women with recurrent pregnancy loss and sole protein S deficiency: a historical control cohort study from Taiwan.

Authors:  Ming-Ching Shen; Wan-Ju Wu; Po-Jen Cheng; Gwo-Chin Ma; Wen-Chu Li; Jui-Der Liou; Cheng-Shyong Chang; Wen-Hsiang Lin; Ming Chen
Journal:  Thromb J       Date:  2016-10-28

Review 9.  Add-ons in IVF programme - Hype or Hope?

Authors:  A K Datta; S Campbell; B Deval; G Nargund
Journal:  Facts Views Vis Obgyn       Date:  2015-12-28

10.  Successful Pregnancy Following Assisted Reproduction in Woman With Systemic Lupus Erythematosus and Hypertension: A Case Report.

Authors:  José Fernando de Macedo; Gustavo Capinzaiki de Macedo; Luciana Aparecida Campos; Ovidiu Constantin Baltatu
Journal:  Medicine (Baltimore)       Date:  2015-09       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.